Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection

SH Safiabadi Tali, JJ LeBlanc, Z Sadiq… - Clinical microbiology …, 2021 - Am Soc Microbiol
SUMMARY The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory disease coronavirus 2 (SARS-CoV-2), has led to millions of confirmed cases and …

Rapid, point‐of‐care antigen tests for diagnosis of SARS‐CoV‐2 infection

J Dinnes, P Sharma, S Berhane… - Cochrane database …, 2022 - cochranelibrary.com
Background Accurate rapid diagnostic tests for SARS‐CoV‐2 infection would be a useful
tool to help manage the COVID‐19 pandemic. Testing strategies that use rapid antigen tests …

Structure of SARS-CoV-2 membrane protein essential for virus assembly

Z Zhang, N Nomura, Y Muramoto, T Ekimoto… - Nature …, 2022 - nature.com
The coronavirus membrane protein (M) is the most abundant viral structural protein and
plays a central role in virus assembly and morphogenesis. However, the process of M …

Rapid assessment of SARS-CoV-2–evolved variants using virus-like particles

AM Syed, TY Taha, T Tabata, IP Chen, A Ciling… - Science, 2021 - science.org
Efforts to determine why new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) variants demonstrate improved fitness have been limited to analyzing mutations in the …

Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases

A Tarke, J Sidney, CK Kidd, JM Dan, SI Ramirez… - Cell Reports …, 2021 - cell.com
T cells are involved in control of SARS-CoV-2 infection. To establish the patterns of
immunodominance of different SARS-CoV-2 antigens and precisely measure virus-specific …

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month …

R Ella, S Reddy, H Jogdand, V Sarangi… - The Lancet Infectious …, 2021 - thelancet.com
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel) …

The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and …

W Wu, Y Cheng, H Zhou, C Sun, S Zhang - Virology journal, 2023 - Springer
Abstract Coronavirus disease 2019 (COVID-19) continues to take a heavy toll on personal
health, healthcare systems, and economies around the globe. Scientists are expending …

Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic

KKW To, S Sridhar, KHY Chiu, DLL Hung… - Emerging microbes & …, 2021 - Taylor & Francis
Without modern medical management and vaccines, the severity of the Coronavirus
Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome (SARS) …

Structural insights into SARS-CoV-2 proteins

R Arya, S Kumari, B Pandey, H Mistry, SC Bihani… - Journal of molecular …, 2021 - Elsevier
The unprecedented scale of the ongoing COVID-19 pandemic has catalyzed an intense
effort of the global scientific community to unravel different aspects of the disease in a short …

[HTML][HTML] The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA

J Cubuk, JJ Alston, JJ Incicco, S Singh… - Nature …, 2021 - nature.com
Abstract The SARS-CoV-2 nucleocapsid (N) protein is an abundant RNA-binding protein
critical for viral genome packaging, yet the molecular details that underlie this process are …